<DOC>
	<DOC>NCT02946424</DOC>
	<brief_summary>This is a double blind, randomized, placebo -controlled clinical trial with the primary goal of determining the osteogenic benefits of simvastatin in acute SCI.</brief_summary>
	<brief_title>Simvastatin to Prevent SCI-Induced Bone Loss</brief_title>
	<detailed_description>Investigators will test if a 1- year course of simvastatin (40 mg daily) will prevent bone loss compared to placebo in the first year following SCI.</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1860 years of age acute SCI (AIS AC) who are enrolled at our center in an ongoing surveillance study. use a wheelchair as their primary mobility mode reside in the greater Denver metropolitan area within 3 months of injury medically stable able to follow directions provide informed consent. have any simvastatin contraindications including: drug allergy, active liver disease, renal dysfunction, concurrent use of drugs that cause myopathy or increase the risk of myopathy with simvastatin therapy (gemfibrozil, niacin, cyclosporine, danazol, amiodarone, dronedarone, ranolazine, calcium channel blockers, colchicine), strong CYP34A inhibitors (itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistatcontaining products), low plasma cholesterol levels, uncontrolled or poorly controlled diabetes, unstable anticoagulation treatment, taking a statin in the preceding 12 months, metabolic bone disease, thyroid disorder, history of bilateral oophorectomy, current use of medications potentially affecting bone health including bisphosphonates, androgenic steroids, estrogenic steroids, antiepileptics, lithium glucocorticoid use for more than 3 months, have received inhaled glucocorticoids in the past 12 months, pregnant or lactating women, women of childbearing potential who are unwilling or unable to use a reliable form of contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>